A study to assess the safety, and blood levels of CTX-187 after single and repeated intravenous doses in healthy volunteers and patients with bacterial infection

2026-525619-15-00 Protocol CTX-187-101 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 22 May 2026 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol CTX-187-101

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 68
Countries 1
Sites 1

Bacterial Infection

Key facts

Sponsor
Centauri Therapeutics Limited
Participant type
Patients, Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Bacterial Infections and Mycoses [C01]
Trial duration
22 May 2026 → ongoing
Decision date (initial)
2026-04-30
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Bacterial Infection

VersionLevelCodeTermSystem organ class
28.0 PT 10060945 Bacterial infection 100000004862

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Centauri Therapeutics Limited

Sponsor organisation
Centauri Therapeutics Limited
Address
First Floor, 5 Fleet Place 5 Fleet Place
City
London
Postcode
EC4M 7RD
Country
United Kingdom

Scientific contact point

Organisation
Centauri Therapeutics Limited
Contact name
Dr. Debra Barker

Public contact point

Organisation
Centauri Therapeutics Limited
Contact name
Dr. Debra Barker

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ongoing, recruiting 68 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ongoing, recruiting
Pharmaceutical Research Associates Group B.V.
Program Management, Van Swietenlaan 6, 9728 NZ, Groningen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2026-05-22 2026-05-22

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2026-03-23 Netherlands Acceptable
2026-04-30
2026-04-30